Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
21 April, 2025
Trial data-sharing made easier with HeSANDA initiative
Latest News: 21 April 2025 TROG Cancer Research is
16 April, 2025
Mark Hughes Foundation grant for innovative SMART trial into brain metastases
LATEST NEWS: 15 April 2025 An innovative trial aimed
